Oncology partnerships Blanver’s strategic partnership with Adalvo for value-added oncology products demonstrates its ability to co-develop and manufacture oncology assets; pursue similar oncology CDMO or co-development deals to leverage its production capabilities.

Regional expansion Licensing activity with Biophytis for Latin America highlights Blanver’s role in regional manufacturing and commercialization and signals opportunities to extend co-development, licensing, or distribution into additional markets including Asia and North America.

Core API focus From excipients to active pharmaceutical ingredients, Blanver now targets high-value APIs and medicines across HIV/AIDS, Hepatitis C, osteoporosis, CNS, and growing areas like Oncology, Hematology and Rare Diseases—ideal for API manufacturing partnerships and finish-dosage collaborations.

Public lab partnerships Ongoing collaborations with public laboratories indicate readiness to engage government procurement channels and public health initiatives for API supply, affordable generics, and essential medicines.

Scale and tech With industrial sites in São Paulo and a substantial workforce, plus a modern tech stack including CRM and digital tools, Blanver is positioned to scale partnerships with larger global players and accelerate deal execution.